DxS announced that the its TheraScreen: K-RAS Mutation Kit will be launched this August in Canada. The company's TheraScreen: K-RAS Mutation Kit has been granted a licence by the regulatory body Health Canada for use as a diagnostic for anti-EGFR therapies and as the companion diagnostic for Amgen’s colorectal cancer therapy, Vectibix (panitumumab).
Following the global distribution agreement signed in 2008, Roche Diagnostics will be distributing and supporting sales of the TheraScreen: K-RAS Mutation Kit in Canada beginning in August of this year.
The availability of the TheraScreen: K-RAS Mutation Kit will allow colorectal cancer patients in Canada to be screened using the DxS diagnostic to assess their suitability for treatment with Vectibix. Studies have shown that patients with the non-mutated K-RAS gene may respond to treatment with Vectibix.
Dr. Kenneth Pritzker, Mount Sinai Services, Toronto, one of the leading centres carrying out K-RAS testing in Canada said This is extremely good news that we have a registered method for K-RAS testing. The DxS K-RAS test is simple to use, highly sensitive and is the companion diagnostic test of choice for assessing a patient’s response to Vectibix.